Shaun Ajinkya, MD
Neurology · Rochester, MNNPI 1952750416
Payments from drug & device makers
Across 160 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$540
- EMD Serono, Inc.$380
- AbbVie$315
- Novartis$200
- Neurelis, Inc.$169
- Biogen$146
- plus $2K from 39 others
What the payments were for
- Food & beverage$3,47696%
- Education$1444%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,620 in reported general payments places this provider in the 70th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $320,295 |
| BriviactBrivaracetam | 39 | $87,912 |
| Nurtec OdtRimegepant Sulfate | 74 | $86,702 |
| Aimovig AutoinjectorErenumab-Aooe | 74 | $62,811 |
| Dimethyl Fumarate | 11 | $48,609 |
| UbrelvyUbrogepant | 28 | $43,049 |
| FycompaPerampanel | 27 | $35,140 |
| Oxtellar XrOxcarbazepine | 22 | $34,535 |
| Lacosamide | 212 | $25,220 |
| AptiomEslicarbazepine Acetate | 16 | $23,619 |
| XcopriCenobamate | 17 | $22,603 |
| VimpatLacosamide | 13 | $19,589 |
| EliquisApixaban | 23 | $19,560 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $17,575 |
| QuliptaAtogepant | 13 | $14,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $49 | $320,29512 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $70 | $110,686116 claims |
| UCB, Inc.Briviact, Vimpat | $540 | $107,50252 claims |
| AbbVieUbrelvy, Qulipta | $315 | $57,91741 claims |
| Eisai Inc.Fycompa | $14 | $35,14027 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $15 | $23,61916 claims |
| SK Life Science, Inc.Xcopri | $65 | $22,60317 claims |
| Neurelis, Inc.Valtoco | $169 | $14,37518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 434 neurology providers in Minnesota.
Other neurology in Rochester
- Sean PittockRochester$3.2M
- Miguel Paz SoldanRochester$2.4M
- Ryan TownleyRochester$2M
- Eoin FlanaganRochester$1.7M
- David KnopmanRochester$1.6M
- Partha GhoshRochester$1.3M
- Wolfgang SingerRochester$1.3M
- Peter DyckRochester$1M
- James BowerRochester$820K
- Jonathan Graff-RadfordRochester$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.